Thermo Fisher Pharma Services: COVID-19 Mobilization
Transforming Medicines with Scale, Flexibility and Expertise
Well before the pandemic, Thermo Fisher committed more than $800M of investments to transform our drug substance, drug product and clinical supply capabilities that deliver on the increasing need for scalability, flexibility and expertise.
These global investments have enabled our clients to respond rapidly in the battle against COVID-19. We are proud to announce that our customers have more than 250 projects leveraging our capabilities in vaccines, antivirals and treatments that typically would have taken years to launch. We are committed to partnering with our clients to solve these challenges and accelerate development and commercialization of COVID-19 treatments, from new projects to rapid scale-up of new COVID-19 indications for existing medicines.
The development and production of vaccines, antivirals and treatments requires a broad range of capabilities and expertise across the supply chain. There are both new modalities and traditional approaches that have shown promising potential to address the pandemic. Our focus has been to create an expanding network of capabilities that gives our customers the rapid scalability, flexibility and deep expertise required to bring molecules to patient.
“Thermo Fisher is proud to support biopharma, academia and government customers to develop and commercialize both therapeutics and vaccines to fight the COVID-19 pandemic. As the pandemic battle wages on, we also recognize that we must continue to be vigilant in delivering critical non-covid19 medicines, because a patient’s need for treatments for cancer, genetic diseases and other conditions doesn’t stop during a pandemic.”
News
Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China November 6, 2020
Thermo Fisher Scientific Announces Plans to Expand Sterile Filling Capacity for Therapies and Vaccines with New Facility in Singapore October 14, 2020
Thermo Fisher Scientific Opens New Bioprocessing Collaboration Center in St. Louis September 9, 2020
Visit our Investment & Innovation page to learn how we’re expanding our capabilities for our customers.
9 Examples of the 250+ Projects We’re Collaborating on with Our Clients
Vaccines
Biological preparation providing active acquired immunity using a weakened version, a fragment or portion of the virus’s DNA.
- Supporting multiple COVID-19 vaccine programs entering human clinical trials, including monoclonal antibodies (mAbs), nucleic acid-based (mRNA) and plasmids.
- Providing clinical packaging and logistics for vaccine trials in Brazil.
- Expanding manufacturing capacity for sterile injectables used to fill a high volume of vaccine doses for BARDA and increasing capacity for both vaccines and therapies in Singapore.
Antivirals
Drugs that inhibits the virus’s ability to replicate inside the human body.
Treatments
Drugs affecting the immune system’s response to an infection by either turning up or down the immune system’s response.
- Rolled out “site to patient” program to ensure clinical trial patients would still receive investigational drug shipments during pandemic.
- Shortened time to fill vials of critical COVID-19 treatment from six weeks to days.
- Accelerated production of a year’s worth of anti-inflammatory treatment in a few months.
Our Customers
- 78% of 800+ clients are emerging biotechs
- Top 20 pharma companies
- Across biopharma, serving 1 million patients per day
Our Work
- 1000+ molecules developed
- 109 new products launched over past 10 years
- 6000+ clinical trial projects supported in 2019
Our Expertise
- ~3,500 scientists and technicians
- ~3,000 quality specialists
- 100+ counties we serve
- 55+ locations across 5 continents
Our Investments
- ~$800M investments by end of 2020 to expand both capacity and capabilities from development to commercial
- Strategically investing around three areas of greatest demand:
- Biologics development and manufacturing
- Cell and gene therapy
- Drug product development and commercial capabilities
